Details for New Drug Application (NDA): 208717
✉ Email this page to a colleague
NDA 208717 describes NEBIVOLOL HYDROCHLORIDE, which is a drug marketed by Alkem Labs Ltd, Ani Pharms, Apotex, Aurobindo Pharma Ltd, Cadila Pharms Ltd, Chartwell Rx, Glenmark Pharms Ltd, Hetero Labs Ltd Iii, Indchemie Health, Macleods Pharms Ltd, Mankind Pharma, MSN, Prinston Inc, Regcon Holdings, Reyoung, Torrent, Unichem, and Watson Labs Inc, and is included in eighteen NDAs. It is available from twenty-five suppliers. Additional details are available on the NEBIVOLOL HYDROCHLORIDE profile page.
The generic ingredient in NEBIVOLOL HYDROCHLORIDE is nebivolol hydrochloride. There are fourteen drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the nebivolol hydrochloride profile page.
The generic ingredient in NEBIVOLOL HYDROCHLORIDE is nebivolol hydrochloride. There are fourteen drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the nebivolol hydrochloride profile page.
Summary for 208717
| Tradename: | NEBIVOLOL HYDROCHLORIDE |
| Applicant: | Cadila Pharms Ltd |
| Ingredient: | nebivolol hydrochloride |
| Patents: | 0 |
Pharmacology for NDA: 208717
| Mechanism of Action | Adrenergic beta-Antagonists |
Medical Subject Heading (MeSH) Categories for 208717
Suppliers and Packaging for NDA: 208717
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| NEBIVOLOL HYDROCHLORIDE | nebivolol hydrochloride | TABLET;ORAL | 208717 | ANDA | Cadila Pharmaceuticals Limited | 71209-058 | 71209-058-01 | 30 TABLET in 1 BOTTLE (71209-058-01) |
| NEBIVOLOL HYDROCHLORIDE | nebivolol hydrochloride | TABLET;ORAL | 208717 | ANDA | Cadila Pharmaceuticals Limited | 71209-058 | 71209-058-04 | 90 TABLET in 1 BOTTLE (71209-058-04) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 2.5MG BASE | ||||
| Approval Date: | Dec 17, 2021 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 5MG BASE | ||||
| Approval Date: | Dec 17, 2021 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 10MG BASE | ||||
| Approval Date: | Dec 17, 2021 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
